We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Clinical Influence of the C-Reactive Protein-to-Albumin Ratio in Patients Who Received Curative Treatment for Gastric Cancer.
- Authors
TORU AOYAMA; MASATO NAKAZONO; KENKI SEGAMI; SHINSUKE NAGASAWA; KAZUKI KANO; TAKANOBU YAMADA; YUKIO MAEZAWA; KENTARO HARA; ITARU HASHIMOTO; HIDEAKI SUEMATSU; HAYATO WATANABE; KOSUKE TAKAHASHI; MASAKATSU NUMATA; HIROSHI TAMAGAWA; NORIO YUKAWA; YASUSHI RINO; TAKASHI OGATA; TAKASHI OSHIMA
- Abstract
Background: We investigated the impact of the pre-surgical C-reactive protein-to-albumin ratio (CAR) on survival and recurrence after curative treatment for gastric cancer. Patients and Methods: This study included 481 patients who underwent curative treatment for gastric cancer between 2013 and 2017. The risk factors for overall (OS) and recurrence-free (RFS) survival were identified. Results: A CAR of 0.05 was regarded as the optimal critical point of classification considering the 3- and 5-year survival rates and patients were divided according to their CAR. The OS rates at 3 and 5 years after surgery were significantly higher at 92.5% and 87.9%, respectively, in the low-CAR group compared with 84.9% and 71.9%, respectively, in the high- CAR group. The corresponding RFS rates were 89.1% and 85.5%, and 81.0% and 72.2%, respectively, also a significant difference. A multivariate analysis demonstrated that the CAR was a significant independent risk factor for the OS and marginally significant independent risk factor for the RFS. In addition, the incidences of pancreatic fistula and abdominal abscess were significantly higher and the rate of introduction of adjuvant chemotherapy significantly lower in the high-CAR group. Conclusion: The CAR was a risk factor influencing survival in patients who underwent curative treatment for gastric cancer. An effective perioperative care plan and surgical strategy need to be developed according to the CAR.
- Subjects
STOMACH cancer treatment; C-reactive protein; CANCER relapse; DISEASE incidence; PANCREATIC fistula
- Publication
In Vivo, 2021, Vol 35, Issue 6, p3475
- ISSN
0258-851X
- Publication type
Article
- DOI
10.21873/invivo.12648